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Caffeine is one of the most widely used psychoactive substances worldwide. 
Although caffeine elicits cognitive benefits, there are concerns regarding caffeine’s 
effects on certain health domains. Acute, aerobic exercise has been shown to improve 
cognition. The effects of aerobic exercise in comparison to caffeine on working 
memory (WM) in non-caffeine and caffeine consumers remains unknown. 
Furthermore, the effects of aerobic exercise in reducing caffeine withdrawal 
symptoms has yet to be examined. In Phase I, twenty-nine non-caffeine and thirty 
caffeine consumers completed a WM assessment (n-back task), followed by aerobic 
exercise and caffeine administration. In Phase II, twenty-five caffeine consumers 
underwent a WM assessment and reported caffeine withdrawal symptoms following a 
12-hour deprivation period. Aerobic exercise and caffeine administration improved 
WM accuracy in both types of consumers and reduced caffeine withdrawal 
symptoms. WM performance was not reduced following caffeine deprivation, hence 
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Summary for Lay Audience  
Caffeine is found in a wide variety of beverages and foods including coffee, tea, soft-
drinks, energy-drinks, chocolate, and medications. Many individuals consume caffeine daily 
to feel alert. Caffeine improves aspects of cognition, which refers to our ability to acquire 
and utilize information. Furthermore, caffeine improves feelings of energy and mood. 
However, caffeine consumption in certain individuals can have negative health effects such 
as increased anxiety and muscle tremors. Caffeine consumption has also been linked to some 
negative health effects for pregnant women and their fetuses, such as delayed growth. 
Another concern with caffeine consumption is withdrawal symptoms, which occur when a 
regular consumer does not consume caffeine. Withdrawal symptoms can include headaches, 
tiredness, decreased mood, irritability, and difficulty concentrating. Thus, it is important to 
determine if there is an alternative for caffeine that can improve cognition, energy, and 
mood, without the negative health effects. The primary aim of this project was to determine 
whether twenty minutes of brisk walking would be comparable to ingesting caffeine on a task 
that measures your ability briefly hold and update information in your mind. The secondary 
aim was to determine whether twenty minutes of brisk walking would be comparable to 
ingesting caffeine in reducing withdrawal symptoms after abstaining from caffeine for 12 
hours. Our findings suggest brisk walking for 20 minutes can improve cognition and help 
reduce caffeine withdrawal symptoms. This research could have an impact on our 
understanding of the relationship between aerobic exercise and cognition, as well as how we 
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Chapter 1 : Introduction and Literature Review 
Caffeine is one of the most widely used psychoactive substances worldwide 
(WHO, 2004). A comprehensive assessment of caffeine consumption from the National 
Health and Nutrition Examination Survey, found approximately 89% of adults in the 
United States (US) consume caffeine regularly (Fulgoni, Keast, & Lieberman, 2015). 
Caffeine is present in numerous products such as coffee, tea, soft-drinks, energy-drinks, 
chocolate, and medications. The cognitive and mood-enhancing benefits of caffeine have 
been cited as one of the primary motivators for its consumption (Temple, Dewey, & 
Briatico, 2010; Yeomans, 2010). Caffeine consumption has been specifically associated 
with increased energy, alertness, self-confidence, positive mood, and cognitive 
performance (Griffiths, Juliano, & Chausmer, 2003). However, for some individuals, 
caffeine consumption has been associated with negative effects such as anxiety and 
muscle tremors (Alsene et al., 2003; Bovim, Naess, Helle, & Sand, 1995; Childs et al., 
2008). Caffeine has also been identified as a reinforcing and potentially addictive 
substance (Ferré, 2016; Hughes et al., 1993). Cessation of caffeine consumption often 
results in withdrawal symptoms such as: headache, fatigue, difficulty concentrating, and 
decreased contentedness (Juliano & Griffiths, 2004). Taken together, these findings 
indicate that although caffeine consumption elicits several benefits to cognition and 
mood, there are several concerns regarding caffeine’s potential negative effects and 
withdrawal symptoms.  
Pharmacokinetics  
  Caffeine (1,3,7-trimethylxanthine) is an alkaloid derived from the nuts, seeds, and 
leaves of numerous plant species (Graham, 1978). Once ingested orally, caffeine is 
rapidly absorbed through the small intestine, allowing entry into the bloodstream, and 
distribution to bodily tissues (Mumford et al., 1996). Caffeine reaches peak plasma level 
in approximately 30 to 60 minutes (Benowitz, 1990). Caffeine is primarily metabolized 
by the liver via the cytochrome P450 enzymes (CYP 1A2), with a half-life of 






exercise have been documented to significantly reduce caffeine’s half-life, while acute 
alcohol consumption, oral contraceptive use, and pregnancy have been shown to 
significantly increase caffeine’s half-life (Benowitz, 1990; Collomp et al., 1991; Knutti et 
al., 1982; Patwardhan et al., 1980).  
Mechanisms of Action  
 Caffeine’s primary mechanism of action occurs via antagonism of adenosine 
receptors in the central nervous system (CNS) (Fredholm et al., 1999). Adenosine is a 
neuromodulator primarily responsible for inhibitory effects in the CNS. The presence of 
caffeine in the synaptic clefts of CNS neurons results in the blockade of adenosine 
binding to adenosine receptors, ultimately promoting “wakefulness” and “alertness”.  
Although caffeine acts as an antagonist at all four adenosine sub-receptors (A1, A2A, A2B, 
A3), its actions are primarily exerted through interactions at A1 and A2A sub-receptors 
(Fredholm et al., 1999). Adenosine receptor antagonism also stimulates release of 
neurotransmitters such as dopamine, norepinephrine, and acetylcholine (Carter et al., 
1995; Fredholm & Jonzon, 1988; Hadfield & Milio, 1989). The release of the 
aforementioned neurotransmitters has been associated with enhanced motor activity, 
arousal, information processing, and attentional control (Acquas et al., 2002; Coull et al., 
1995; Powell, Iuvone, & Holtzman, 2001).  
Caffeine Sources and Intake  
Caffeine is present in a growing number of foods, beverages, and supplements. 
Beyond traditional sources such as coffee, tea, and soft-drinks, caffeine is being added to 
candy, gum, and pre-workout supplements (Drewnowski & Rehm, 2016). In a nationally 
representative sample of US adults, coffee was found to be the most widely used source 
of caffeine (64%), followed by soft-drinks (18%), and tea (16%) (Fulgoni et al., 2015). In 
Canada, coffee is the second most consumed beverage by adults and accounts for 
approximately 80% of caffeine consumption, followed by tea (12%), and soft-drinks 
(6%) (Garriguet, 2008). The amount of caffeine in the above sources varies depending on 






States Department of Agriculture (USDA) and the Canadian Nutrient File (CNF; See 
Appendix 13). In Canada, the average daily caffeine intake for adults is approximately 
2.4mg/kg of body weight (equivalent to approximately 173 mg/day for an individual 
weighing the Canadian average of 72.03 kg) (Chou, 1992; Statistics Canada, 2017).  
Caffeine Consumption: Risks and Benefits  
 Caffeine consumption has been associated with risks and benefits to human health 
and well-being. Extensive systematic reviews examining caffeine’s effects on human 
health suggested caffeine intake below 400 mg/day in healthy adults was not associated 
with adverse health effects (Nawrot et al., 2003; Wikoff et al., 2017). However, for a 
subset of individuals and for certain populations, caffeine consumption may result in 
negative health outcomes. For instance, one of the risks associated with caffeine 
consumption is increased anxiety/anxiety-related symptoms. Several studies have 
indicated a subset of individuals experience symptoms such as nervousness and 
restlessness after consuming caffeine (Alsene et al., 2003; Childs et al., 2008). One 
proposed hypothesis suggests possession of genetic variants of the ADORA2A and/or 
CYP1A2 genes, which are associated with adenosine receptors and caffeine metabolism, 
may be associated with heightened sensitivity to caffeine (Alsene et al., 2003; Childs et 
al., 2008; Fulton et al., 2018). In a study investigating the effect of caffeine consumption 
in school-aged children, total weekly caffeine intake was a significant predictor of 
anxiety after controlling for covariates such as diet, demographics (e.g., sex, school), and 
lifestyle (e.g., sleep hours, exercise frequency), indicating caffeine may play a unique 
role in inducing anxiety-related symptoms in childhood (Richards & Smith, 2015). 
Furthermore, adults with pre-existing anxiety disorders have been documented to 
experience exacerbated anxiety symptoms post-caffeine consumption (Bruce et al., 1992; 
Nardi et al., 2009).  
Another risk associated with caffeine consumption in certain individuals is 
increased muscle tremors. Bovim and colleagues (1995) detected reduced motor 






Similarly, in a study examining psychomotor tremors in both low (x̅ =37.07 mg/day) and 
moderate (x̅ = 316.2 mg/day) caffeine consumers, greater motor tremors were observed 
following caffeine consumption in both groups (Sands et al., 2015). A recent review of 
factors affecting tremors in surgeons found caffeine consumption negatively impacted 
surgical dexterity. The study authors encouraged reduction of caffeine consumption prior 
to conducting a surgical procedure to maintain dexterity (Fargen, Turner, & Spiotta, 
2016).  
Caffeine use has been associated with both dependence and withdrawal symptoms 
upon cessation (Hughes et al., 1991; Strain, Mumford, Silverman, & Griffiths, 1994). A 
small proportion of caffeine users (13%) display clinically significant levels of 
dependence consisting of “continued use despite psychological or physical harm, 
difficulty stopping caffeine use, and using more caffeine than intended” (Juliano & 
Griffiths, 2004; Meredith, Juliano, Hughes, & Griffiths, 2013). A larger proportion of 
caffeine users report experiencing a wide range of withdrawal symptoms at varying 
severities including: headache, fatigue, decreased contentedness, and decreased alertness 
(Juliano & Griffiths, 2004; See Section: Caffeine Withdrawal: Subjective and Cognitive 
Effects). 
When considering subsets of the population vulnerable to the effects of caffeine, 
women planning to become pregnant or who are pregnant, have been identified as being 
at a greater risk of experiencing adverse health effects due to caffeine consumption. 
During pregnancy, the rate of caffeine clearance is significantly reduced, promoting 
caffeine accumulation in the body. The accumulated caffeine passes the placental barrier, 
potentially resulting in a disrupted neonatal environment (Knutti et al., 1982). Although 
numerous studies have investigated the effects of caffeine consumption on both maternal 
and fetal health, the results have been mixed. Several studies and reviews have found 
caffeine consumption was associated with negative health outcomes such as: delayed 
conception, increased risk of spontaneous abortion, preterm birth, low birth weight, and 
fetal growth restriction (Bech et al., 2005; Brent et al., 2011; Hahn et al., 2015; Maslova 






health agencies such as Health Canada recommend lower caffeine intake limits (i.e., 
<300mg/day) for reproductive-aged women than for the general population (i.e., 
<400mg/day; Nawrot et al., 2003).  
 Although specific risks are present with caffeine consumption for a proportion of 
individuals, caffeine is also associated with benefits to several health domains. Caffeine 
consumption has been associated with improved metabolic health outcomes (e.g., 
decreased Type II diabetes risk, increased insulin sensitivity, etc.), decreased risk of 
neurological disorders (e.g., Parkinson’s disease), and enhancements to human behaviour 
(e.g., cognitive performance, athletic-related performance, and mood; For an in-depth 
review see:  Nawrot et al., 2003; Pourshahidi et al., 2016). The remainder of this section 
will examine caffeine-induced benefits to cognition.  
Caffeine and Cognition 
Caffeine has been associated with improvements to multiple cognitive domains. 
For instance, caffeine is associated with improved information processing, attention, and 
specific types of memory (i.e., short-term, episodic, spatial). Caffeine administration has 
consistently elicited faster reaction times in both simple and choice reaction time tasks 
(Lieberman et al., 1987; Smit & Rogers, 2000). When examining attention, caffeine has 
marked effects on measures of sustained attention in both “normal” and “impaired” 
conditions, such as following sleep deprivation. Under “normal” conditions, caffeine 
administration (200 mg) improved accuracy on both auditory and visual vigilance tasks 
(Fagan, Swift, & Tiplady, 1988; Fine et al., 1994). Furthermore, caffeine (200 mg) 
improved the number of detected stimuli and reduced reaction times during a 45-minute 
visual vigilance task (Olson et al., 2010). Foxe and colleagues (2012) found that 
participants who completed the sustained attention to response task (SART) following 
caffeine consumption (50 mg) decreased omission errors (not responding to targets) by 
50% compared to placebo.  
Caffeine exerts similar effects on sustained attention under “impaired” conditions. 






resulted in similar performance in a vigilance task compared to non-sleep deprived 
controls (McLellan et al., 2005). Kamimori and colleagues (2005) tested participants who 
underwent a 29-hour wakeful period on the Psychomotor Vigilance Test (PVT). 
Individuals who were provided multiple doses of caffeine during the 29-hour wakeful 
period committed less attentional lapses and maintained baseline PVT performance 
throughout the entire testing period. Studies examining caffeine’s effects on different 
types of memory have found variable results, with some studies detecting benefits and 
others finding null effects (Nehlig, 2010). The following section will focus on caffeine 
and working memory.   
Caffeine and Working Memory 
 Working memory (WM) has been conceptualized as a system that provides 
storage and manipulation of information necessary for cognitive tasks (Baddeley, 1992). 
Previous studies show mixed effects of caffeine administration on WM. Addicott and 
Laurienti (2009) found administering 250 mg of caffeine to regular caffeine consumers 
(2-5 cups of coffee/day) following either 30 hours of caffeine abstinence or normal 
caffeine use resulted in improved accuracy (% correct responses) on the n-back task 
(continuous performance task assessing WM capacity) in both the abstained and normal 
state. Haskell and colleagues (2005) examined the effect of either 75mg or 150mg of 
caffeine in both caffeine (x̅ = 217mg/day) and non-caffeine consumers (x̅ = 20mg/day). 
Caffeine administration (150mg) significantly improved reaction time on the numeric 
WM task in both types of consumers (Haskell et al., 2005). A randomized, double-blind 
investigation of the effects of energy drink ingredients on cognitive performance 
examined the effects of 200 mg of caffeine on verbal (letter-stimuli), object (shape-
stimuli), and spatial (shape-stimuli in differing locations) WM tasks. Caffeine reduced 
reaction time on the most difficult load of the verbal WM task and increased sensitivity 
(an accuracy index composed of hit rate and false alarm rate) across all loads of the 






Personality type has been found to moderate the effects of caffeine on WM. A 
randomized, double-blind, placebo-controlled study examining caffeine, WM, and 
personality type (introvert, extrovert) found 200 mg of caffeine improved performance 
(% correct responses) on the 3-back load in extraverts (Smillie & Gokçen, 2010). 
Furthermore, a study examining the effect of caffeine and personality type on several 
components of WM detected similar results at a lower caffeine dose (65mg). Caffeine 
interacted with extraversion, improving two components of WM (articulatory loop and 
central executive), while also improving simple reaction time and speed of information 
encoding across both personality types, suggesting a unique interaction between 
extraversion, caffeine, and WM (Smith et al., 2013). A number of studies have not 
detected a caffeine-induced improvement to WM (Childs & De Wit, 2006; Koppelstaetter 
et al., 2008; Smith, 1999; Warburton, 1995). Warburton (1995) found no change to WM 
following caffeine ingestion, but did cite high WM performance in the placebo group, 
allowing a small margin for caffeine-driven improvement. Smith (1999) did not find 
overall improvement on the WM tasks (serial recall task, running memory task, and 
spatial memory task) in the caffeine condition, but did detect improved encoding of new 
information in a masked categorical search task, indicating perhaps the tasks chosen to 
assess WM were not sensitive enough to detect subtle caffeine-driven changes. Although, 
Koppelstaetter and colleagues (2008) did not detect accuracy or reaction time differences 
between caffeine and placebo administration on the n-back task, the highest load assessed 
in their paradigm was 2-back and previous studies examining the effect of substances 
such as nicotine on cognition have indicated the 3-back load is the most sensitive to the 
drug effect (Loughead et al., 2009). Koppelstaetter et al (2008) did however determine 
via functional magnetic resonance imaging (fMRI) that caffeine modulated neuronal 
activity in frontal brain regions associated with executive and attentional functions during 
the WM task. In concert, these findings suggest caffeine administration influences WM 
processes.  






 Caffeine has been identified as a reinforcing and addictive substance in murine 
models and humans (Griffiths & Woodson, 1988; Hughes et al., 1991). Early research on 
human caffeine withdrawal determined caffeine consumers (3-7 coffee cups/day) who 
underwent double-blind interleaved periods of caffeinated (100mg) and decaffeinated 
coffee consumption displayed withdrawal symptoms, particularly headache, on 
decaffeinated days. Furthermore, the presentation of headache predicted self-
administration of caffeinated coffee (Hughes et al., 1991). Several studies have replicated 
the presence of withdrawal symptoms following caffeine deprivation with larger sample 
sizes (Silverman et al., 1992), as well as characterized the doses at which withdrawal 
symptoms occur (Evans & Griffiths, 1999). Caffeine doses as low as 100 mg per day 
have been shown to produce withdrawal symptoms upon cessation (Juliano & Griffiths, 
2004).  
Juliano and Griffiths (2004) conducted an extensive review of human caffeine 
withdrawal studies with the objective of characterizing and empirically validating 
reported symptoms. Withdrawal symptoms met validity criteria if there was “statistical 
demonstration of the symptom in six or more studies that include two or more double-
blind studies that used methodologies in which the conclusion of caffeine withdrawal 
effects was not confounded by direct effects of caffeine” (Juliano & Griffiths, 2004). The 
following ten caffeine withdrawal symptoms met full validity criteria: headache, fatigue, 
decreased energy/activeness, decreased alertness, drowsiness, decreased contentedness, 
depressed mood, difficulty concentrating, irritability, and foggy/not clear headed. 
Caffeine withdrawal symptoms occur 12 to 24 hours after abstinence and can persist for 
several days at varying intensities (Griffiths & Woodson, 1988). Administration of 
caffeine post-deprivation has been shown to reduce withdrawal symptom presence and 
severity (Addicott & Laurienti, 2009). Although expectancy effects have been raised as a 
potential confound in relation to caffeine withdrawal, a recent balanced-placebo study 
examining caffeine dose (caffeinated versus decaffeinated) and expectancy (told 






symptoms or cognitive performance, suggesting a pharmacological basis for caffeine 
withdrawal (Juliano, Kardel, Harrell, Muench, & Edwards, 2019).    
Alongside the subjective effects of caffeine withdrawal, negative effects on 
cognitive performance have been detected. Lane and Phillips-Bute (1998) found 
overnight caffeine abstinence in regular caffeine consumers (2-10 coffee cups/day) 
slowed reaction times and reduced accuracy on a vigilance task. James (1998) replicated 
these findings in regular caffeine consumers (3-5 caffeine beverages/day) over a longer 
deprivation period (24-hour) on a character recognition task, which assesses information 
transfer and short-term memory. Similarly, Yeomans and colleagues (2002) found a 24-
hour caffeine abstinence period resulted in slower reaction times and increased errors on 
the Rapid Visual Information Processing (RVIP) task.  However, studies have suggested 
the effects of caffeine withdrawal may be reversed. Yeomans et al., (2002) determined 
administering 1 mg/kg of caffeine after an overnight abstinence period restored RVIP 
task performance (i.e., decreased reaction times and increased response accuracy). An 
investigation of caffeine deprivation on cognitive performance, as measured by a choice-
reaction and n-back task, determined 30 hours of deprivation in regular caffeine 
consumers (2-5 coffee cups/day) reduced performance on choice reaction time (Addicott 
& Laurienti, 2009). Furthermore, administration of 250 mg of caffeine post deprivation 
reduced reaction time on the choice-reaction task and improved accuracy on the 1-back 
load of the n-back task (Addicott & Laurienti, 2009). These findings suggest caffeine 
deprivation results in withdrawal symptoms and reduces performance on a subset of 
cognitive tasks, which are both restored by caffeine administration.  
Caffeine Withdrawal Reversal  
James (1998) first posited the concept of withdrawal reversal, suggesting caffeine 
has limited direct effects, but rather operates by “reversing” withdrawal effects. In 2005, 
James and Rogers outlined that several laboratory studies required an overnight 
abstinence period before conducting cognitive and subjective assessments, inducing a 






reduced the negative effects of withdrawal, such as tiredness, rather than represented a 
caffeine-driven benefit. To address this concern, several studies have incorporated low to 
non-caffeine consumer groups, ad-libitum caffeine consumption, and long-term 
withdrawal periods to delineate whether caffeine induces direct effects (Addicott & 
Laurienti, 2009; James & Rogers, 2005; Warburton, Bersellini, & Sweeney, 2001). 
Heterogeneous results have been reported, with some studies finding direct effects of 
caffeine (Addicott & Laurienti, 2009; Childs & deWit, 2006; Haskell et al., 2005 Smith, 
Christopher, & Sutherland, 2013), while others finding evidence supporting caffeine 
withdrawal reversal (James, 1998; James, Gregg, Kane & Harte, 2005).  
Alternative Modalities to Enhance Cognition: Acute Exercise  
Given the aforementioned concerns associated with caffeine consumption, 
examining alternative modalities to improve cognitive performance is critical. Acute 
exercise (single bout) has been suggested as a potential intervention to improve cognitive 
performance. Previous studies have shown reliable improvements in cognition following 
acute exercise (Chang, Labban, Gapin, & Etnier, 2012; Lambourne & Tomporowski, 
2010; Tomporowski, 2003). In a meta-analysis conducted by Chang et al. (2012), the 
authors found acute exercise (aerobic, anaerobic, resistance, and combination) had a 
small (Hedge’s g = 0.097), but positive effect on cognition. Furthermore, these positive 
cognitive effects were found during exercise, immediately following exercise, and after a 
delay (Chang et al., 2012). Regarding the assessment of cognitive performance, tasks 
gauging executive functions such as the Stroop Task, were more sensitive to the effects 
of acute exercise in comparison to other cognitive task types (Chang et al., 2012). 
In addition to the above findings, Chang and colleagues (2012) examined 
potential moderators of the acute exercise and cognition relationship including: timing of 
cognitive assessment, exercise duration, and exercise intensity. When examining timing 
of cognitive assessments, testing immediately following exercise resulted in the largest 
effect (Cohen’s d = 0.108), followed by testing after a delay (d = 0.103), and testing 






testing, 11-20 minutes of exercise produced the greatest effect (d = 0.262). Exercise 
intensity had differential effects depending on the timing of cognitive testing. Positive 
effects on cognition were only observed for very light (d = 0.152), light (d = 0.169), and 
moderate intensity exercise (d = 0.120) when cognitive testing occurred immediately 
after exercise. When cognitive testing occurred after a delay, positive effects on cognition 
were found at every intensity except very light (d = -0.133). Chang et al.’s (2012) 
findings suggest acute exercise lasting 11-20 minutes, at an intensity ranging from light 
to moderate, may produce the greatest post-exercise cognitive benefit.  
Further studies examining the relationship between exercise intensity and 
cognitive performance have suggested moderate intensity may confer the greatest post-
exercise cognitive benefit, particularly in executive functioning (EF) tasks (McMorris, 
Sproule, Turner, & Hale, 2011; McMorris & Hale, 2012). McMorris and colleagues 
(2011) conducted a meta-analysis of studies utilizing acute, moderate intensity exercise to 
enhance EF as assessed by several different tasks (e.g., Flanker Task, Switching Visual 
Attention Task, Stroop Task, etc.). Acute, moderate intensity exercise had a strong, 
beneficial effect on reaction times in EF tasks (Hedges’ g = -1.41), but a small, negative 
effect on accuracy (Hedge’s g = 0.40). In a subsequent investigation of the differential 
effects of exercise intensities on cognition speed and accuracy, McMorris and Hale 
(2012) detected a small but positive effect size on overall cognitive performance 
(Hedge’s g = 0.14). The two studies together suggest the increased arousal elicited by 
moderate intensity may result in faster information processing speed. Regarding 
accuracy, the small effect may be due to the cognitive assessments lacking the 
appropriate sensitivity to detect subtle exercise-induced changes to accuracy (McMorris 
& Hale, 2012). 
Concerns have been raised regarding whether cardiorespiratory fitness influences 
the relationship between acute exercise and cognitive performance. Chang et al. (2014) 
addressed these concerns in an investigation of cardiorespiratory fitness, acute exercise, 
and executive functioning. Healthy college-aged adults completed a maximal graded 






low, moderate, and high fitness groups. Individuals in all fitness groups were assessed on 
the Stroop Task, which measures executive functioning, pre- and post- completion of 20 
minutes of cycling (65% of participant VO2 max). Participants performed better on the 
Stroop Task post-exercise, irrespective of cardiorespiratory fitness. However, on the 
incongruent condition of the Stroop Task, moderate fitness individuals exhibited the 
fastest reaction times, while high fitness individuals exhibited the slowest reaction times, 
indicating cardiorespiratory fitness may affect specific domains of information 
processing, but not overall performance.  
Beyond cognitive functioning, acute exercise has also been shown to provide 
other psychological benefits such as improved mood, feelings of energy, and well-being 
(Maraki et al., 2005; Loy et al., 2003; Bartholomew, Morrison, & Ciccolo, 2005). 
Alongside psychological benefits, acute exercise also confers physical health benefits 
such as improved cardiovascular health, skeletal muscle, and immune function 
(Rosenwinkel, Bloomfield, & Arwady, 2001 ; Schenk & Horowitz, 2007 ; Rowbottom & 
Green, 2000). Thus, acute exercise is a promising alternative for caffeine in that it has 
been documented to improve cognitive, psychological, and physical health.  
Exercise and Cognition: Mechanisms  
Several neurobiological mechanisms have been proposed to underlie the observed 
exercise-induced benefits to cognition. The following mechanisms will be reviewed 
below: (i) neurogenesis and angiogenesis, (ii) increased neurochemical release, and (iii) 
changes to cerebral blood flow and neurotransmitter release. Neurogenesis and 
angiogenesis refer to the production of new neurons and blood vessels, respectively. Non-
human animal studies have indicated aerobic exercise training resulted in neurogenesis, 
specifically in the hippocampus, a brain region associated primarily with memory (Creer, 
Romberg, Saksida, van Praag & Bussey, 2010; van Praag, Christie, & Gage, 1999). In 
addition, following aerobic exercise training, angiogenesis was detected in brain regions 
nearby the hippocampus. Some studies have found increased neurogenesis was associated 






Ryzhenko, Toshkov, & Rhodes, 2008). Taken together, these findings suggest although 
there are reliable aerobic exercise-induced structural changes to the brain, the dose of 
exercise required and the manner in which the changes promote cognitive function 
remain unclear.  
Regarding neurochemical changes, two neural growth factors have been identified 
as being heavily involved in the exercise-induced benefits to cognitive performance. 
Brain-derived neurotrophic factor (BDNF) is a neurotrophin, a protein involved in the 
development, function, and survival of neurons (Barde, 1994). BDNF has been identified 
as a key component in the neurochemical cascades associated with neuroplasticity 
(Huang et al., 2006). Neuroplasticity facilitates learning through modifying neural 
connections (Hennigan, O’Callaghan, & Kelly, 2007). Non-human animal studies have 
identified that a single bout of exercise increased BDNF levels in the brain (Rasmussen et 
al., 2009). Furthermore, a systematic review of acute exercise studies in humans 
determined that 69% of studies examining acute, aerobic exercise in healthy individuals 
resulted in a “mostly transient increase in serum or plasma BDNF concentration” 
(Knaepen, Goekint, Heyman, & Meeusen, 2010). The transient increases in BDNF post-
exercise may thus promote neuroplasticity in regions contributing to cognition. 
The second neurotrophic factor that has been documented to play a role in the 
exercise-cognition relationship is insulin-like growth factor 1 (IGF-1; Voss, Nagamatsu, 
Liu-Ambrose, & Kramer, 2011). In non-human animals, aerobic exercise has resulted in 
elevated IGF-1 production (Trejo, Carro, & Torres-Aleman, 2001). One study found IGF-
1 and BDNF work in tandem to promote neurogenesis and angiogenesis, particularly in 
the hippocampus (Lopez-Lopez, LeRoith, & Torres-Aleman, & 2004; Trejo, Carro, & 
Torres-Aleman, 2001). Increases to both neurotrophic factors have been linked to 
increased neuroplasticity and other brain network-related changes, however the manner 
in which these changes impact cognition warrant further investigation.  
The aforementioned mechanisms underlying changes to brain structure typically 






cerebral blood flow (CBF; Vissing, Andersen, & Diemer, 1996) and increased 
neurotransmitter release (Dishman, 1997; Wang et al., 2000) are more likely to underlie 
the cognitive changes following acute exercise. Several non-human animal studies have 
indicated acute exercise-induced changes to CBF (Delp et al., 2001; Vissing, Andersen, 
& Diemer, 1996). Human studies have detected changes to the oxygenation of CBF with 
concomitant improvements to cognitive performance following acute exercise (Bediz et 
al., 2016; Yanagisawa et al., 2010). Regarding neurotransmitter release, non-human 
animal studies have consistently shown changes to the release of acetylcholine, 
dopamine, epinephrine, and norepinephrine following acute exercise (Kashihara et al., 
2009; Poehlman et al., 1992; Soya et al., 2007). Several human studies have also detected 
changes to release of neurotransmitters, namely dopamine and norepinephrine, during 
and following acute exercise (McMorris et al., 2008; Wang et al., 2000). Although 
several neurotransmitters have been associated with the facilitation of cognitive processes 
(Blokland, 1995), the nature of the relationships between acute exercise-induced 
neurotransmitter release and cognition remains to be elucidated.  
Acute Exercise: Restoring Cognitive Performance and Reducing Withdrawal 
Symptoms during Cessation of other Substances  
As mentioned previously caffeine deprivation often results in negative effects on 
cognitive performance (Addicott & Laurienti, 2009; James, 1998; Phillips-Bute, 1998; 
Yeomans et al., 2002 and withdrawal symptoms (Juliano & Griffiths, 2004). With respect 
to cognitive performance, there is no literature to support the tenet that cognitive deficits 
seen through caffeine deprivation can be restored following an acute bout of exercise. 
One indirect non-inferiority study found light-to-moderate intensity exercise 
pragmatically increased cognition to a similar level as nicotine in a non-deprived 
smoking model (Fagan, Guirguis, Smith, Sui, Rollo, and Prapavessis, unpublished). The 
authors concluded that exercise is a healthier alternative to nicotine for cognitive 







Cessation of other substances such as nicotine, alcohol, opioids, and 
benzodiazepines have also been associated with withdrawal symptoms (WHO, 2018). 
Although withdrawal management is often pharmacological in nature, in the context of 
smoking cessation (Haasova, Warren, Ussher, Van Rensburg, Faulkner, & Cropley, 2013; 
Roberts, Maddison, Simpson, Bullen, & Prapavessis, 2012) and recently alcohol 
cessation (Stoutenberg, Rethorst, Lawson, & Read, 2016), acute exercise has been 
successfully employed as an intervention to reduce the intensity and frequency of 
withdrawal symptoms and cravings. In two comprehensive systematic and meta-analysis 
reviews, Roberts et al., (2012) using aggregate data and Haasova et al., (2013) using 
individual participant data found weighted mean differences in both “desire to smoke” [-
1.90 and-2.04 points, respectively] and ‘strength of desire to smoke” [-2.41 and -1.91 
points, respectively] that favored the acute exercise condition over the control condition 
following a temporary period of abstinence. The effect sizes found in these studies ranged 
from d = .4 to 1.9, which are considered moderate-to-large in size (Cohen, 1988). 
Furthermore, craving reduction effects lasted up to 30 minutes post-exercise (Ussher, 
Cropley, Playle, Mohidin, & West, 2009). Unfortunately, the mechanisms through which 
exercise exerts its craving effect are not well understood. Potential mechanisms of action 
that have received some support include affect and mood (De Jesus & Prapavessis, 2018), 
shifts in attention (Janse Van Rensburg et al., 2012), and cortisol secretion (Roberts et al., 
2015). 
Regarding tobacco withdrawal symptoms, light and moderate intensity exercise 
significantly reduced symptoms, while vigorous exercise increased symptoms (Roberts et 
al., 2012). Withdrawal symptoms positively affected by acute exercise included stress, 
difficulty in concentration, tension, restlessness, depression, and irritability (Roberts et 
al., 2012). Although the mechanisms underlying exercise-induced reductions to 
withdrawal symptoms remain unclear, several biological and cognitive mechanisms have 
been proposed. Changes in beta-endorphins, opioids, and cortisol have been identified as 
factors potentially mediating the exercise-induced reductions in tobacco withdrawal 






been identified as a psychophysiological marker that changes following smoking 
cessation and exercise, highlighting its potential role in elucidating exercise-driven 
withdrawal symptom reduction (Stein et al., 1996; Sandercock, Bromley, & Brodie, 
2005). Cognitive changes such as shifts in the allocation of cognitive resources, such as 
attention, may also be involved in reducing specific withdrawal symptoms (Ekkekakis & 
Acevedo, 2006). Several of the withdrawal symptoms reported in the tobacco cessation 
context overlap with caffeine cessation (Irons et al., 2016). The shared symptomatology 
lends to assessing the utility of acute exercise in reducing caffeine withdrawal symptoms 
during caffeine deprivation.   
 Summary 
 There is robust evidence that caffeine leads to improvement in cognitive 
performance. Furthermore, when considering the health-concerns associated with 
caffeine consumption for specific individuals and subsets of the population, examining 
alternative modalities to improve cognitive performance is warranted. An acute bout of 
exercise has also shown to enhance cognitive performance, while providing additional 
health benefits. To date, the effects of acute exercise in comparison to caffeine on 
cognitive performance in both non-caffeine and caffeine users remain unknown. 
Furthermore, cognitive deficits and withdrawal symptoms accompany periods of caffeine 
deprivation among caffeine users. It also remains unknown whether acute exercise can 
reverse these cognitive deficits and withdrawal symptoms to the same extent as caffeine.  
Objectives  
The objectives of the present study are as follows:  
Phase I 
i) To determine the effects of an acute bout of moderate intensity aerobic 
exercise and caffeine administration on working memory (WM) in both 






Phase II   
i)  To determine whether a 12-hour caffeine deprivation period in caffeine 
consumers increases caffeine withdrawal symptoms and reduces WM 
performance.   
ii)  To determine whether an acute bout of moderate intensity aerobic exercise 
and caffeine administration can reduce caffeine withdrawal symptoms and 
restore WM performance.   
Hypotheses 
The hypotheses of the present study are as follows: 
Phase I 
i) In comparison to baseline WM performance, aerobic exercise and caffeine 
administration will improve WM comparably in both non-caffeine and 
caffeine consumers. 
Phase II  
ii) A 12-hour caffeine deprivation period in caffeine consumers will increase 
caffeine withdrawal symptoms and reduce WM performance.  
iii) Aerobic exercise or caffeine administration will reduce caffeine 









Chapter 2 : Methods 
Participants  
The inclusion criteria consisted of: (1) aged 18-64 years, (2) ability to read and 
write in English, and (3) consumption of less than 30 milligrams of caffeine per day (non-
caffeine consumer) or consumption of greater than or equal to 150 milligrams of caffeine 
per day (caffeine consumer). The exclusion criteria consisted of: (1) contraindications to 
exercise (as assessed by the Physical Activity Readiness Questionnaire), (2) self-reported 
cognitive difficulties, (3) self-reported taking of medication for depression or anxiety, 
and (4) pregnancy. In (data analyses (See: Table 1). In Phase II, twenty-five participants 
(caffeine consumers) completed study procedures.  
 
                                Table 1. Demographics: Means and Standard Deviations (SD) 
 Caffeine 
Consumers 
 (n = 30) 
Non-Caffeine 
Consumers 
(n = 29) 
Age 24.1 (4.8) 
 
24.8 (3.4) 





72.7 (15.1) 70.1(12.2) 
Education (%) 
   Undergraduate  
   Graduate  










Caffeine Intake (mg) 
   Weekly  








Time of Last Caffeine Consumption (h)  10.33 (9.31)  
Years of Caffeine Consumption 6.7 (4.1)  
Preferred Type of Caffeine Administration  Coffee  
Physical Activity (minutes of MVPA/week) 
 
1213 (752.8) 1324.19 (1044.296) 








Study Design  
Phase I 
Phase I utilized a randomized counterbalanced crossover design such that each 
participant was randomly assigned treatment order (i.e., caffeine administration followed 
by exercise or exercise followed by caffeine administration) but completed both 
treatments irrespective of being non-caffeine and caffeine consumers. Treatments were 
conducted on separate days  
Phase II  
Phase II involved only caffeine consumers and utilized a randomized design such 
that each participant was randomly assigned to receiving either caffeine administration or 
exercise following a 12-hour caffeine deprivation period. Randomization was completed 
using a computer-generated numbers table.  
 
 






Primary Outcome Measure: Working Memory  
Working memory (WM) was assessed through the n-back task. The n-back task 
has been widely used in the cognition literature to gauge WM, as it requires both short-
term recognition of and operation on stimuli (Baddeley, 1992; Conway, Kane, Bunting, 
Hambrick, Wilhelm, & Engle, 2005). The n-back task consists of a series of stimuli that 
are presented rapidly on a screen, with the participant deciding whether the target stimuli 
matches the stimuli ‘n’ items back (Jonides, Schumacher, Smith, Lauber, Awh, 
Minoshima, & Koeppe, 1997). 
 
 
Figure 2. n-back task (Jonides et al., 1997) 
The n-back task was run on Inquisit (version 4.0.8.0; Millisecond Software, 
2008).  Instructions for the task are presented on the screen and a practice phase precedes 
the evaluation. The participant must score a minimum of 75% of the trials correctly 
during the practice phase to proceed to the evaluation. The 75% accuracy threshold was 
deemed appropriate for mitigating the learning effect on the n-back task in a previous 
study examining WM in smokers and non-smokers (Fagan, Guirguis, Smith, Sui, Rollo, 






The n-back task utilized in this study employed letter stimuli. Each letter stimulus 
was presented upon the computer screen for 500 milliseconds (ms), followed by a 2000 
ms interstimulus (blank screen). The number of stimuli presented changed depending on 
the working memory load. For example: 0-back = 48 letters, 1-back = 51 letters, 2-back = 
51 letters, and 3-back = 54 letters. The individuals would complete each load (0-back, 1-
back, 2-back, and 3-back) three times in a randomized order. A correct response would 
be when the participant pressed the letter ‘A’ on the keyboard which would indicate the 
letter in the sequence is the same as the target letter ‘n’ items back. In the 0-back, the 
target letter precedes the assessment for that block, for example, the program states “the 
target is W”, hence every time a ‘W’ appears on the screen the individual should press 
the ‘A’ key. In the 1-back, a correct response would be if the letter and the consecutive 
letter are the same, for example, ‘F’, ‘interstimulus’, ‘F’. In the 2-back, a correct response 
would be if a letter matched a previous letter that appeared 2 back in the sequence, for 
example ‘T’, ‘interstimulus’, ‘X’ ‘interstimulus’, ‘T’. In the 3-back, a correct response 
would be if a letter matched a previous letter that appeared 3 back in the sequence, for 
example ‘M’, ‘interstimulus’, ‘P’, ‘interstimulus’, ‘T’ ‘interstimulus’, ‘M’. Reaction time 
(ms) and accuracy (percentage of errors) were tabulated for each load. Previous research 
has identified the 3-back load as being the most sensitive to drug administration 
(Loughead, Wileyto, Valdez, Sanborn, Tang, Strasser, Ruparel, Ray, Gur &, Lerman, 
2009). Furthermore, the 3-back load has also been shown to be sensitive to acute exercise 
(Tomporowski et al., 2003; Fagan, Guirguis, Smith, Sui, Rollo, and Prapavessis, 
unpublished).  
Other Measures  
Demographics 
The following information was collected: age, sex, weight (kg), and education 
level. 






Acute and chronic caffeine history (i.e., approximate time of last caffeine 
consumption, amount of years regularly consuming caffeine, preferred type of caffeine 
administration) was assessed. Consumption of drugs (i.e., smoking, alcohol) in the past 
18 hours was assessed. No participants reported drug consumption 18 hours prior to the 
experiment. No participants were smokers.  
Physical activity 
The Physical Activity Readiness Questionnaire (PAR-Q; Thomas, Reading, & 
Shephard, 1992) was utilized to assess ability to participate in physical activity safely. 
The PAR-Q is appropriate to administer to individuals aged 15-69 years (Thomas, 
Reading, & Shephard, 1992). The PAR-Q has seven items, each with only two possible 
response options: yes or no. If a participant indicated yes to any of the seven items they 
were deemed not able to participate in physical activity and were thus excluded from the 
study (See Appendix 3). 
The Short Questionnaire to Assess Health-enhancing Physical Activity 
(SQUASH; Wendel-Vos, Schuit, Saris, & Kromhout, 2003) was administered to assess 
the frequency, duration, and perceived effort of physical activity during an average week 
in four domains: commuting (e.g. walking to school), leisure time (e.g. sports), household 
(e.g. washing dishes), and work/school (e.g. walking and standing between working at a 
desk) (Wendel-Vos et al., 2003). Frequency and duration are fillable options, such that 
the participant is able to indicate the number of days per week, as well as the amount of 
hours and minutes they partake in each activity, while perceived effort has three possible 
options: slow/light, moderate, and fast/intense. An assessment of the test-retest reliability 
of the SQUASH in an adult Dutch population determined acceptable reliability 
(Spearman’s correlation = 0.58) (Wendel-Vos et al., 2003). An investigation of the 
validity of the SQUASH via doubly labelled water, determined the SQUASH is a valid 
self-report tool for assessing physical activity energy expenditure (Campbell, Gaston, 
Gray, Rush, Maddison, & Prapavessis, 2016; See Appendix 12).  






 The Caffeine Consumption Questionnaire Revised (CCQ-R; Irons, Bassett, 
Prendergast, Landrum, & Heinz, 2016) was administered to assess the consumption of 
caffeine-containing products (i.e. beverages, foods, and drugs) during an average week. 
The CCQ provides images of caffeine containing products to aid in the estimation of the 
serving size of products consumed. The modified CCQ has been shown to have 
acceptable reliability (Pearson product moment correlation, r = 0.77). An investigation of 
the validity of the CCQ in gauging weekly caffeine consumption determined the CCQ 
has acceptable criterion validity (>85% inter-rater agreement) (Irons et al., 2016; See 
Appendix 10). CCQ responses were converted to caffeine intake in milligrams/week 
using the reference values in Harland (2000; See Appendix 8). 
 Caffeine Withdrawal 
The Caffeine Withdrawal Symptom Questionnaire (CWSQ; Juliano, Huntley, 
Harrell, & Westerman, 2012) was utilized to assess the type and severity of caffeine 
withdrawal symptoms experienced by the caffeine-consumers. The CWSQ uses twenty-
three items which focus on seven symptom clusters: (1) fatigue/drowsiness, (2) low 
alertness/difficulty concentrating, (3) mood disturbances, (4) low sociability/motivation 
to work, (5) nausea/upset stomach, (6) flu-like feelings, and (7) headache. The CWSQ 
also includes nine additional items for consideration, four of which have not yet been 
empirically validated. Severity of each symptom is assessed on a five-point scale ranging 
from 0 (not at all) to 4 (extremely). A higher score reflects greater number of symptoms 
and symptom severity.  The CWSQ remains in the initial stages of validation and further 
studies are warranted to assess its reliability (Juliano et al., 2012; See Appendix 11). 
Intervention  
Aerobic Exercise 
 The exercise intervention consisted of a single bout of moderate intensity aerobic 
exercise completed on a Woodway PPS treadmill (Woodway, Waukesh, WI). The 






intensity, and a 2.5 minute cool-down walk. Moderate intensity exercise was defined as 
40 to 60% of Heart Rate Reserve (HRR; Karvonen, Kentala, & Mustala, 1957; ACSM, 
2013). HRR was calculated using the formula (HRmaximum= 220-age) – (HRrest). HRrest was 
taken in a seated position prior to exercise with a heart rate monitor. HR during exercise 
was also taken with a heart rate monitor. The researcher controlled the speed and incline 
of the treadmill to ensure the participant exercised within their moderate intensity HRR 
range.  
 Caffeine Administration 
The caffeine administration intervention consisted of oral ingestion of powdered 
caffeine. Each participant ingested 1.2mg/kg (body weight) of powdered caffeine 
(Sigma–Aldrich Foundation, St Louis, MO) dissolved in 100mL of water (Heatherly, 
Hayward, Seers, & Rogers, 2005). The participant then waited in a seated position for 20 
minutes to permit caffeine absorption (Mumford, Benowitz, Evans, Kaminski, Preston, 
Sanneurd, Silverman, & Griffiths, 1996).  
Procedure  
The conduct of the study adhered to the Declaration of Helsinki (World Medical 
Association, 2013) and the Handbook for Good Clinical Research Practice (WHO, 2005). 
Ethical approval was granted from the Western University’s Research Ethics Board 
(#110797) (See Appendix 1). All participants read the Letter of Information, had his/her 
questions pertaining to the study answered, and signed a Consent Form prior to study 
participation.  
Participants were recruited from Western University via online advertisements 
email, and word-of-mouth. Participants were initially screened for eligibility via email or 
an in-person meeting. Screening questions pertained to age (i.e. between 18 and 64), 
ability to read and write in English, self-reported caffeine consumption (<30mg/day or 






on a treadmill for twenty minutes at a moderate intensity), self-reported cognitive 
difficulties, self-reported taking of medication for depression or anxiety, and pregnancy.  
For those eligible, a first session was scheduled at the Exercise and Health 
Psychology Lab (EHPL, www.ehpl.uwo.ca) at Western University. The first session 
began with administration of the PAR-Q. If a participant indicated yes to any of the seven 
items on the PAR-Q, they were deemed not able to participate in physical activity and 
were thus excluded from the study. Upon completion of the PAR-Q, participants were 
given the demographic questionnaire, caffeine and drug history questionnaire, SQUASH, 
CCQ-R, and CWSQ (caffeine consumers only) to complete.  
A non-caffeine consumer was defined as an individual who consumes less than 30 
mg of caffeine/day (Kennedy & Haskell, 2011). A caffeine consumer was defined as an 
individual who consumes equal to or greater than 150 milligrams of caffeine a day, which 
approximately equates to the amount of caffeine in a cup of brewed coffee (Harland, 
2000).  Non-caffeine consumers completed two one-hour sessions on two separate days 
(one exercise session and one caffeine administration session). Caffeine consumers 
completed three sessions on three separate days (one exercise session, one caffeine 
administration session, and one caffeine deprivation session). The order of sessions (i.e. 
caffeine administration followed by exercise or exercise followed by caffeine 
administration) was randomized. Participants were scheduled at approximately the same 
time to mitigate diurnal effects.  
For both non-caffeine and caffeine consumers, blood pressure (BP) was taken in a 
seated position with an electronic sphygmomanometer (MPOW). Resting heart rate (HR) 
was taken in a seated position with a heart rate monitor (Polar RS100). Weight was 
measured using the Health-O-Meter Professional weight scale (Health-O-Meter 500 KL, 
Boca Ration, FL) to the nearest 0.1kg. Participants then completed the baseline n-back 
task (lasting approximately 10 to 15 minutes) on a portable computer in isolation. Upon 






session or the caffeine administration session. HR and BP were again taken at the end of 
each treatment session followed by the n-back task. 
 Participants returned on the second day and followed the same protocol to 
complete the treatment session they did not undergo on day one. Caffeine consumers 
underwent one additional session, which required a 12-hour caffeine deprivation period 
prior to arrival on the third day. Participants were told the researcher would be 
biologically confirming caffeine abstinence through a saliva swab, when in fact no 
salivary caffeine assays were conducted. This was simply a strategy to increase caffeine 
deprivation compliance (Rogers et al., 2003). Participants’ BP and HR were taken in a 
seated position upon arrival. They then completed the CWSQ and the n-back task to 
assess caffeine-deprived performance. Upon completion of the n-back task, participants 
were randomized into receiving either the exercise session or caffeine administration 
session. At the end of either session, the CWSQ and n-back were administered again. At 
the end of the experimental protocols, participants’ email addresses were entered into a 
draw to win a twenty-five-dollar gift card.  
Sample Size Analysis  
Phase I  
Giles and colleagues (2012) detected a change in WM accuracy (composite score 
of hit rate and false alarm rate) between placebo and caffeine administration (Cohen’s d = 
0.418). Fagan, Guirguis, Smith, Sui, Rollo, and Prapavessis, unpublished detected a change 
in WM accuracy (% errors) between baseline and aerobic exercise (Cohen’s d = 0.511). 
Based on the above findings, to be adequately powered to detect differences from baseline, 
caffeine, and aerobic exercise, a conservative approach of using a small-to-moderate effect 
size f = 0.20, power = 0.80, and alpha = 0.05, generated a sample size of 28 individuals 
(Cohen 1969; Cohen, 1988; Faul, Erdfelder, Lang, & Buchner, 2007).  






 In developing the Caffeine Withdrawal Symptom Questionnaire (CWSQ), Juliano 
and colleagues (2012) detected a 2.69-point reduction in withdrawal symptoms (Cohen’s 
d = 0.866) when caffeine was administered following a 16-hour caffeine deprivation 
period. Based on the above findings, to be adequately powered to detect the effects of 
caffeine administration following an overnight deprivation period, an approach of using 
the effect size of d =0.866, power = 0.80, and alpha = 0.05, generated a sample size of 13 
individuals (Cohen 1969; Cohen, 1988; Faul, Erdfelder, Lang, & Buchner, 2007).  
Primary and secondary outcome analyses 
Phase I  
Repeated measures ANOVAs were conducted across baseline, caffeine, and 
exercise for both accuracy (% errors) and RT (ms) for non-caffeine and caffeine 
consumers on the n-back task. Analyses focused on the 3-back (primary outcome) and 2-
back (secondary outcome) loads specifically. Means, standard deviations, and 95% 
confidence intervals associated with both non-caffeine and caffeine-consumers at all n-
back loads are presented in Table 2.  
Phase II  
Repeated measures ANOVAs were conducted across non-deprived, caffeine-
deprived, and post-caffeine withdrawal symptom scores as well as non-deprived, 
caffeine-deprived and post-exercise withdrawal symptom scores (primary outcome). 
Repeated measures ANOVAs were also conducted across non-deprived, caffeine-
deprived and post-caffeine accuracy (% errors) and RT (ms) on the n-back task, as well 
as non-deprived, caffeine-deprived, and post-exercise accuracy (% errors) and RT (ms) 
on the n-back task (secondary outcome). Analyses focused on the 3-back and 2-back 
loads specifically. 
For both phases, following significant repeated measures ANOVAs, Bonferroni-
corrected post-hoc t-tests were conducted. The level of significance was accepted at p 






in figures represent standard deviation (SD). Data were analyzed using IBM SPSS 






Chapter 3 : Results  
Treatment of Data 
Missing data. One non-caffeine participant had no data recorded during the post-
exercise session and thus was not included in the analyses. Two BP measures from one 
participant were not recorded due to equipment malfunction and thus were omitted from 
the BP dataset and fidelity check. 
Outliers. n-Back trials were excluded if trial RT <150ms (Miller & Low, 2000) 
and if the trial was identified as an outlier (>1.5 times the interquartile range above the 
upper quartile and below the lower quartile) via boxplots. Less than 3% of total trials 
were excluded from the n-Back data set.  
Manipulation check (MC). Paired sample t-tests were conducted to determine 
whether a time effect (participants performing better on second assessment compared to 
first assessment irrespective of treatment) was present. Factorial repeated measures 
ANOVAs (2 treatment: caffeine, exercise by 2 treatment order: caffeine first, exercise 
first) were also conducted to determine whether treatment by order effects were present.  
Non-caffeine consumers MC. All paired sample t-tests were non-significant [3-
back accuracy, t(28) = 1.231, p = 0.229, d =0.190. 3-back RT, t(28) =-1.218, p = 0.233, d 
=0.235. 2-back accuracy, t(28) = 1.231, p = 0.228, d =0.313. 2-back RT, t(28), =-0.800, p 
=0.430, d=0.141], indicating no time effects were present. Three-back, factorial repeated 
measures ANOVAs found no significant interaction effect for accuracy, F(1,12) =2.292, 
p = 0.156, η2 = 0.160 but a significant interaction effect for RT, F(1,12) = 5.866, p 
=0.032, η2 = 0.328. For the 2-back, factorial repeated measures ANOVAs found no 
significant interaction effects for accuracy, F(1,12) =0.359, p = 0.560, η2 = 0.029 or RT, 
F(1,12) =0.519, p =0.485, η2 = 0.041. Taken together, these data show that no treatment 
by order effect was present except for RT on the 3-back. 
Caffeine consumers MC. All paired sample t-tests were non-significant [3-back 






=0.165. 2-back accuracy, t(29) = 0.743, p = 0.464, d =0.187. 2-back RT, t(29), =0.556, p 
=0.582, d=0.140], indicating no time effects were present. Three-back, factorial repeated 
measures ANOVAs revealed a significant interaction effect for accuracy, F(1,14) =4.807, 
p = 0.046, η2 = 0.256. No significant interaction effect was found for RT, F(1,14) = 
0.288, p =0.600, η2 = 0.020. For the 2-back, no interaction effect was found for accuracy, 
F(1,14) =0.244, p = 0.629, η2 = 0.017 or RT, F(1,14) =0.142, p =0.712, η2 = 0.010. These 
data, taken together, suggest there was no treatment by order effect present except  for 
accuracy on the 3-back. 
Fidelity check. A repeated measures ANOVA, followed by post-hoc t-tests were 
conducted across pre-exercise, during, and post-exercise treatment for heart rate (HR) 
combining both caffeine and non-caffeine consumers. There was a significant effect for 
HR [F(2,116) = 754.442, p < 0.000, η2 = 0.929]. Paired sample post-hoc t-tests uncovered 
significant increases between pre-exercise and during exercise: t(59)=33.97, p <0.000, 
d=5.480, and significant decreases during exercise and post-exercise t(59)=30.260, p 
<0.000, d=4.846. A paired sample t-test was conducted between HR prior to caffeine 
administration and HR post caffeine administration (20 minutes) combining both caffeine 
and non-caffeine consumers. There was a significant decrease in HR [t(58) = 5.117, p < 
0.000, d =0.584]. Descriptive HR data can be seen in Table 2 and Table 3.  
Paired sample t-tests were conducted between systolic blood pressure (SBP) pre-
exercise and post-exercise, as well as pre-caffeine and post-caffeine. There was no 
significant difference in SBP following exercise: [t(57) =0.240, p = 0.811, d =0.048]. 
There was a significant difference in SBP following caffeine: [t(57) =-2.925, p = 0.005, d 
=-0.546 ]. Paired sample t-tests were also conducted between diastolic blood pressure 
(DBP) pre-exercise and post-exercise as well as pre-caffeine and post-caffeine 
administration. There was no significant difference in DBP following exercise: [t(57) 
=0.527, p = 0.600, d = 0.118]. There was no significant difference in DBP following 
caffeine: [t(57) =0.125, p = 0.125, d = -0.283]. Descriptive BP data can be seen in Table 







 Non-Caffeine Consumers Caffeine 
Consumers 
Both Consumers  
Pre-
Exercise 
71.76 (10.82) 74.36 (11.51) 73.15 (11.01) 
Exercise  121.52 (5.69) 120.18 (5.40) 121 (5.57) 
Post 
Exercise 
74.51 (13.10) 76.96 (10.72) 75.88 (11.93) 
Table 2. Exercise Treatment HR, Values are means and (SD), HR (beats/min) 
 
 Non-Caffeine Consumers Caffeine 
Consumers 
Both Consumers  
Pre-
Caffeine  
69.03 (9.03) 69.96 (10.2) 69.64 (9.45) 
Post-
Caffeine  
64.45 (9.37) 63.61 (10.5) 64.05 (9.71) 
























 117.86 (12.15) 
Post-
Exercise 



























 72.69 (10.76) 






















































 73.31 (10.82) 
Table 5. Caffeine Treatment BP, Values are means and (SD), SBP and DBP (mmHg)  
 
Group equivalency (Phase II only). Independent t-tests revealed no significant 
treatment group differences (between participants randomized to caffeine and participants 
randomized to exercise) for age: t(23)=1.231, p = 0.231, d = 0.490, weight: t(23) = 0.086, 
p= 0.932 , d = 0.034, years of caffeine consumption: t(23) =1.105 , p =0.281, d =0.437, 
daily caffeine consumption (mg): t(23) = 0.257, p=0.799, d =0.103, non-deprived 
caffeine withdrawal scores: t(23): -0.121, p= 0.905, d = 0.048, and MVPA per week 
(minutes): t(23)= -0.208, p=0.837, d=0.084. Chi-square tests revealed no significant 
group differences for sex χ² (1, n = 25) = 1.066, p = 0.302, Phi = -0.206 and education χ² 
(1, n = 25) = 0.051, p = 0.821, Phi =0.045.  
 
 
Phase I  






Non-caffeine consumers. A repeated measures ANOVA for 3-back accuracy was 
statistically significant: F(2,56)=3.315, p=0.044, η2 =0.106 (see Figure 3). Paired sample 
post-hoc t-tests uncovered non-significant differences between baseline and the caffeine 
condition: t(28)=2.60, p=0.052, d =0.345, baseline and the exercise condition: t(28) 
=2.30, p=0.107, d =0.313, and caffeine and exercise condition t(28) =0.25, p=1.000, d 
=0.0148. A repeated measures ANOVA for 3-back RT was not statistically significant: 









Figure 3. Changes to accuracy following treatments. Values are means ± SD. *p <0.05 








































Caffeine consumers. A repeated measures ANOVA for 3-back accuracy was 
statistically significant: F(2,58)=6.479, p=0.003, η2 =0.183 (see Figure 5). Paired sample 
post-hoc t-tests uncovered significant differences between baseline and the caffeine 
condition: t(29) =2.818, p=0.027, d =0.512, and baseline and the exercise condition: t(29) 
=3.454, p=0.006, d =0.599. No significant difference was found between the caffeine and 
exercise condition t(29) =0.667, p=1.000, d = 0.112. A repeated measures ANOVA for 3-








































Secondary Outcome (2-back) 
Non-caffeine consumers. A repeated measures ANOVA for 2-back accuracy was 
not statistically significant F(2,56) =2.644, p=0.080, η2 =0.086. A repeated measures 
ANOVA for 2-back RT was statistically significant F(2,56) =4.595, p =0.014, η2 =0.141. 
Paired sample post-hoc tests uncovered significant differences between baseline and the 
caffeine condition only: t(28)=2.786, p=0.028, d =0.527.  
Caffeine consumers. A repeated measures ANOVA for 2-back accuracy was 
statistically significant F(2,58) =9.179, p=0.000, η2 =0.240. Paired sample post-hoc t-tests 
uncovered significant differences between baseline and the caffeine condition only: t(29) 
=3.90, p=0.002, d=0.679. A repeated measures ANOVA for 2-back RT was not 
statistically significant F(2,58) =2.239, p =0.116, η2 =0.072.  
 
 































M SD 95% CI 
Baseline  
3-back Error % 14.33 5.43 
                  [12.30, 16.36] 
3-back RT 
761.12 228.71 [675.72, 846.52] 
2-back Error % 
8.26 7.28 [5.54, 10.98] 
2-back RT 665.80 174.99 [600.45, 731.14] 
1-back Error % 5.53 7.69 [2.66, 8.41] 
1-back RT 608.62 128.98 [560.45, 656.78] 
0-back Error % 4.13 7.34 [1.39, 6.88]  
0-back RT 496.29 96.54 [460.24, 532.33] 
Caffeine                                                                                      
3-back Error % 11.26 6.49 [8.84, 13.69] 
3-back RT  714.19 208.50 [636.34, 792.05] 
2-back Error % 4.37 3.87 [2.93, 5.82] 
2-back RT 615.66 166.00 [553.67, 677.65] 
1-back Error % 2.23 4.28 [0.65, 3.85] 






0-back Error % 1.50 4.28 [0.00, 0.31] 
0-back RT 487.97 85.96 [455.87, 520.06] 
Exercise                                                                                 
3-back Error % 10.49 7.25  [7.78, 13.20] 
3-back RT 737.50 254.86 [640.71, 834.29] 
2-back Error % 5.88 4.97 [4.02, 7.74] 
2-back RT  641.85 219.53 [559.87, 723.82] 
1-back Error % 5.60 1.81 [-0.12, 1.23] 
1-back RT  543.03 140.22 [490.67, 595.39] 
0-back Error % 0.694 2.34 [0.18, 1.57] 
0-back RT 488.9 78.63                  [459.53, 518.26] 
 
 





M SD 95% CI 
Baseline  
3-back Error % 13.06 7.00 
[10.40, 15.72] 
3-back RT 






2-back Error % 
7.23 10.60 [3.20, 11.26] 
2-back RT 667.62 189.00 [595.72, 739.52] 
1-back Error % 2.93 9.096 [-0.53, 6.389] 
1-back RT 551.38 162.42 [489.60, 613.16] 
0-back Error % 0.87 1.55 [0.28, 1.46]  
0-back RT 473.88 59.49 [451.25, 496.51] 
Caffeine                                                                                      
3-back Error % 10.44 8.13 [7.35, 13.54] 
3-back RT  744.93 212.36 [664.15, 825.70] 
2-back Error % 4.35 9.69 [0.664, 8.03] 
2-back RT 577.34 151.62 [519.66, 635.01] 
1-back Error % 3.54 8.83 [0.183, 6.90] 
1-back RT  511.56 94.87 [475.47, 547.65] 
0-back Error % 1.19 2.88 [0.09, 2.29] 
0-back RT 458.82 70.98 [431.82, 485.82] 
Exercise                                                                                 
3-back Error % 10.77 7.59  [7.89, 13.60] 






2-back Error % 5.47 8.69 [2.17, 8.78] 
2-back RT  609.61 145.28 [554.35, 664.87] 
1-back Error % 2.00 8.20 [-1.00, 6.00] 
1-back RT  526.70 127.88 [478.05, 575.33] 
0-back Error % 2.00 3.60 [0.00, 3.00] 
0-back RT 478.34 95.88                  [441.87, 514.81] 
 
Table 6. Means, SDs, 95% CI for Non-Caffeine and Caffeine Consumers for all n-back 
loads  
Phase II 
Primary Outcome (Caffeine Withdrawal Symptoms)  
A repeated measures ANOVA conducted between non-deprived CWSQ, deprived 
CWSQ, and post-caffeine CWSQ scores was statistically significant: F(2,24)=11.058, p = 
0.001, η2 = 0.501 (seed Figure 7). Paired sample post-hoc t-tests uncovered significant 
differences between baseline and the deprived condition, t(11)= -3.856, p = 0.008, 
d=1.35, as well as between the deprived condition and post-caffeine administration: 








Figure 7. Changes to caffeine withdrawal symptoms from the non-deprived state , 
following 12-hour deprivation, and post caffeine administration. Values are means ± SD. 
*p <0.05 
A repeated measures ANOVA conducted between non-deprived CWSQ, deprived 
CWSQ, and post-exercise CWSQ scores was also statistically significant: F(2,24)=5.786, 
p =0.009 η2 = 0.325 (see Figure 8). Paired sample post-hoc t-tests uncovered a significant 
difference between baseline and the deprived condition, t(12) = -2.861, p=0.043, 
d=1.095, but a non-significant difference between the deprived condition and post 













Secondary Outcome (3-back) 
 A repeated measures ANOVA for 3-back accuracy between non-deprived, 
deprived, and post-caffeine was not statistically significant: F(2,22) =0.651, p = 0.531, η2 
= 0.056 (See Figure 9). A repeated measures ANOVA for 3-back RT between non-
deprived, deprived, and post-caffeine was not statistically significant: F(2,22) =0.684, p = 
0.515, η2 = 0.059 (See Figure 10). A repeated measures ANOVA for 3-back accuracy 
between non-deprived, deprived, and post-exercise was not statistically significant: 
F(2,24) = 1.801, p = 0.187, η2 = 0.131 (See Figure 11). A repeated measures ANOVA for 
3-back RT between non-deprived, deprived, and post-exercise was not statistically 
significant: F(2,24) =0.486, p = 0.621, η2 = 0.039 (See Figure 12).  
Figure 8. Changes to caffeine withdrawal symptoms from the non-deprived state , following 



















































Withdrawal: 3-Back Reaction Time
Figure 9. Accuracy comparison between non-deprived state, following 12-hour deprivation, and 
post-caffeine administration. Values are means ± SD. *p <0.05 
Figure 10. RT comparison between non-deprived state, following 12-hour deprivation, and post-






































Figure 12. RT comparison between non-deprived state, following 12-hour deprivation, and post-














Withdrawal: 3-Back Reaction Time
Figure 11. Accuracy comparison between non-deprived state, following 12-hour deprivation, and 







Secondary Outcome (2-back)  
A repeated measures ANOVA for 2-back accuracy between non-deprived, 
deprived, and post-caffeine was not statistically significant: F(2,22) =1.086, p = 0.355, η2 
= 0.090. A repeated measures ANOVA for 2-back RT between non-deprived, deprived, 
and post-caffeine was not statistically significant: F(2,22) = 1.467, p = 0.252, η2 = 0.118. 
A repeated measures ANOVA for 2-back accuracy between non-deprived, deprived, and 
post-exercise was not statistically significant: F(2,24) =0.549, p =0.584, η2 = 0.044. A 
repeated measures ANOVA for 2-back RT between non-deprived, deprived, and post-
exercise was not statistically significant: F(2,24) = 1.442, p = 0.256, η2 = 0.107. 
Relations between caffeine-deprived WM performance and caffeine withdrawal 
symptoms.  
Bivariate correlations were conducted between deprived WM performance (3-
back) and deprived withdrawal symptoms (CWSQ) scores. A Pearson correlation 
between deprived 3-back WM accuracy and deprived withdrawal symptoms in the post-
caffeine group was not statistically significant: r(10) =0.209, p= 0.514. A Pearson 
correlation between deprived 3-back WM accuracy and deprived withdrawal symptoms 







Chapter 4 : Discussion 
The present investigation sought to determine the effects of acute, aerobic 
exercise in comparison to caffeine administration on working memory (WM) in non-
caffeine and caffeine consumers. Additionally, the investigation sought to examine the 
utility of acute, aerobic exercise in reducing WM deficits and subjective withdrawal 
symptoms induced by caffeine deprivation. To begin, I will discuss the Phase I findings, 
followed by the Phase II findings.  
Phase I  
WM performance: Accuracy 
In comparison to baseline WM accuracy, caffeine administration and acute, 
aerobic exercise improved WM accuracy in non-caffeine (3-back load only) and caffeine 
consumers (2- and 3-back loads). In non-caffeine consumers, WM accuracy improved 
following both caffeine administration and acute, aerobic exercise. In line with our 
hypothesis, caffeine administration and aerobic exercise conferred comparable 
improvements to accuracy (absolute percent difference: 2.62%, 2.29% and relative 
percent difference: 20.1%, 17.5% respectively). Caffeine administration conferring a 
slightly greater accuracy benefit may be due in part to the novelty of caffeine as a 
substance for non-caffeine consumers, as prior research has suggested non-caffeine 
consumers display heightened physiological and psychological responses to caffeine 
(Kennedy & Haskell, 2011). Furthermore, the non-caffeine consumers in this study 
reported high physical activity participation (1324 minutes of MVPA/week), suggesting 
tolerance of a single-bout of aerobic exercise with little fatigue and discomfort (Chiu & 
Barnes, 2003). Previous studies have identified that exercise tolerance is implicated in 
exercise-cognition investigations as individuals who do not regularly exercise are more 
likely to experience fatigue, which has been associated with impaired cognitive 
performance (Brown & Bray, 2015). It is also important to note that our findings 
contribute to the body of literature (Haskell et al., 2005; Childs & deWit, 2006; Addicott 






and does not rely completely on the reversal of withdrawal symptoms, as non-caffeine 
consumers would not be expected to experience caffeine withdrawal.  
In caffeine consumers, aerobic exercise improved accuracy to a greater extent 
(absolute percent difference: 3.84%, relative percent difference: 26.8%) than caffeine 
administration (absolute percent difference: 3.07%, relative percent difference: 21.4%). 
Aerobic exercise conferring a greater benefit to WM accuracy than caffeine may be due 
in part to caffeine tolerance (Evans & Griffiths, 1991). The caffeine dose administered 
(1.2mg/kg) equates to less than the mean daily caffeine consumption reported by the 
caffeine group (301.5mg/day), suggesting these consumers have likely developed some 
level of tolerance to the caffeine-driven cognitive effects. Similarly, to the non-caffeine 
consumers, caffeine consumers also reported regular participation in physical activity 
(1213 minutes of MVPA/week) supporting the notion that a single-bout of aerobic 
exercise was tolerated comfortably by this group. It is important to address that a 
treatment by order effect was detected for accuracy on the 3-back load in caffeine 
consumers, suggesting receiving caffeine on the the first day may have resulted in 
improved performance on the second day following acute, aerobic exercise, although 
treatment order was counterbalanced. A carry-over effect may have been present and thus 
utilizing a wash-out period greater than 24-hours may be required in future 
investigations.  
Overall, our findings that WM accuracy improvements were detected in both 
groups (non-caffeine and caffeine consumers) at only the 2- and 3-back WM loads is in 
line with previous work which stated higher WM loads are most sensitive to drug and 
behavioural intervention effects (Loughead et al., 2009). Furthermore, our work 
substantiates prior findings that acute caffeine administration (Addicott & Laurienti, 
2009) and acute exercise improve WM accuracy (Tomporowski et al., 2003).  
WM performance: RT 
 Caffeine administration improved WM RT in comparison to baseline only in non-






WM speed in non-caffeine and caffeine consumers at the 2- and 3-back loads. These 
findings differ from those reported by Haskell et al., (2005) and McMorris et al., (2011). 
Diverging results could be due to the wide range in administered caffeine doses (Kaplan 
et al., 1997), type of cognitive task administered, and exercise intensity (Smit & Rogers, 
2000; McMorris et al., 2011). Prior work by our group also detected no changes to RT on 
the n-back task following acute, aerobic exercise at a moderate intensity (Fagan et al., 
unpublished). It is important to note when examining the WM speed and accuracy 
findings in concert, improved WM was not due to a speed-accuracy trade-off (Reed, 
1973). In other words, individuals were not committing less errors on the n-back task at a 
cost to response speed. Prior work has suggested caffeine may improve accuracy in 
cognitive tasks via increased alertness (Giesbrecht, Rycroft, Rowson, & DeBruin, 2010) 
and modulation of neuronal activity in regions associated with attention (Koppelstaetter 
et al., 2008). When considering acute, aerobic exercise it has been proposed that exercise 
selectively affects the activation and allocation of attentional resources (Sanders , 1983; 
Tomporowski et al., 2003). 
Phase II 
Caffeine Withdrawal Symptoms 
 A twelve-hour caffeine deprivation period increased subjective caffeine 
withdrawal symptoms (14.88-point increase on CWSQ from non-deprived state), which 
was in line with our hypothesis and prior work examining caffeine withdrawal (Juliano & 
Griffiths, 2004). Moreover, caffeine administration and aerobic exercise reduced caffeine 
withdrawal symptoms (12.91-point reduction, 8.07 point-reduction, respectively). Our 
results are in line with previous work suggesting caffeine re-administration reduces 
caffeine withdrawal symptoms (Addicott & Laurienti, 2009). Furthermore, our study 
suggests acute aerobic exercise demonstrates utility in reducing caffeine withdrawal 
symptoms, which is a novel finding, as well as provides further evidence that a single-
bout of aerobic exercise improves “alertness”, “feelings of energy”, and mood (Maraki et 






in the exercise and tobacco withdrawal literature, which determined acute, aerobic 
exercise successfully reduced withdrawal symptoms such as stress, difficulty 
concentrating, tension, restlessness, depression, and irritability (Roberts et al., 2012).  
 When conceptualizing the caffeine deprived phase of this investigation, the notion 
of non-inferiority was explored. Non-inferiority trials assess whether a novel intervention 
is not unacceptably lesser than a standard of care in clinical research (Rehal et al., 2016). 
Non-inferiority trials promote the comparison of advantages that a novel therapy may 
have over a standard therapy, such as fewer side effects or lower costs (Bouman et al., 
2015). Caffeine use has been associated with withdrawal symptoms upon cessation in 
certain individuals and thus “caffeine-related disorders” have been introduced into the 
Diagnostic and Statistical Manual (DSM-5; Hughes et al., 1991; Strain, Mumford, 
Silverman, & Griffiths, 1994; Juliano & Griffiths, 2004; Addicott, 2014). Although 
caffeine-related disorders have been added to the DSM-5, diagnostic criteria for caffeine-
use disorder have not been solidified due to uncertainties regarding caffeine’s abuse 
potential and clinically relevant symptomology (APA, 2013). The lack of quantifiable 
diagnostic criteria during the time of this investigation barred calculating an appropriate 
non-inferiority margin for caffeine withdrawal symptoms to subsequently compare 
caffeine administration to acute, aerobic exercise for caffeine withdrawal relief.   
WM performance 
In contrast to the caffeine withdrawal symptoms, a 12-hour caffeine deprivation 
period did not reduce WM performance in caffeine consumers. No significant changes to 
WM accuracy or speed were detected between the non-caffeine deprived and caffeine-
deprived conditions. These findings were not in line with our hypothesis or with work 
conducted by Yeomans et al., 2002. Differing results may be due to the duration of 
caffeine-deprivation utilized in our paradigm. Some studies have employed a 24-hour 
caffeine deprivation period which may have resulted in greater caffeine withdrawal 
severity and in turn greater cognitive deficits (Yeomans et al., 2002; Giles et al., 2012). 






investigations of caffeine withdrawal that detected a caffeine-deprivation induced 
cognitive deficit, a variety of cognitive tasks were used (e.g., Rapid Visual Information 
Processing task, Attention Network Test) and thus perhaps, the n-back alone may not have 
been the most sensitive to detect subtle WM deficits (Heatherely et al., 2004). 
Alternatively, the caffeine consumers in our study completed several iterations of the n-
back task, thus the practice effect may have bolstered WM performance in the caffeine-
deprived trials.  
Addicott and Laurienti (2009) have also posited participants may exert more effort 
during the caffeine-deprived state to compensate for “withdrawal-related fatigue”. Given 
that WM performance did not suffer following the 12-hour deprivation period, 
improvement to WM via caffeine administration or acute, aerobic exercise was unlikely. 
However, it is important to note that WM performance remained stable following both 
treatments. Previous literature has suggested that caffeine withdrawal effects worsen with 
time and withdrawal related fatigue could result in deteriorating performance on cognitive 
tasks (Juliano & Griffiths, 2004; Rogers et al., 2005). Thus, since we detected no change 
to WM performance, the caffeine administration and acute, aerobic exercise treatments my 
have buffered the caffeine-deprivation effects.  
When examining the WM performance and caffeine withdrawal symptoms in 
concert, 12-hours of caffeine deprivation did not affect WM performance and caffeine 
withdrawal symptoms in the same manner. Twelve-hours of caffeine deprivation resulted 
in no significant decrements to WM performance as assessed by the n-back task, 
however, caffeine withdrawal symptoms significantly increased. Bivariate correlations 
between deprived WM accuracy (3-back load) and deprived CWSQ scores were weakly, 
positively correlated, suggesting that caffeine-deprivation may operate on cognition and 
caffeine withdrawal symptoms via distinct mechanisms, however, further investigations 
are needed to disentangle the effects of caffeine-deprivation.  






The present investigation had numerous strengths. The recruitment of a non-
caffeine consumer group allowed our study to address methodological concerns 
highlighted in previous studies, as we could further explore whether caffeine-driven 
enhancements to cognition represent direct caffeine effects or the reversal of caffeine 
withdrawal effects. Furthermore, the use of both cognitive (n-back task) and self-report 
(CWSQ) measures following 12-hour caffeine deprivation enabled comparison of 
objective and perceived effects of caffeine withdrawal. When considering study design, 
the use of a within-subject counterbalanced design in Phase I provided advantages in 
terms of reducing variability associated with individual differences, as subjects act as 
their own control, as well as minimization of order effects via counterbalancing. Another 
strength included administration of the caffeine and aerobic exercise treatments on 
separate days, as this minimized carry-over effects and fatigue experienced when 
undergoing cognitive testing. The use of a between-subjects randomized design in Phase 
II provided advantages in reducing the number of times the n-back was conducted. 
Finally, the caffeine dosing utilized in our investigation accounted for participant body 
weight, while also being within doses typically consumed in real-world contexts.  
Despite the aforementioned strengths, there are limitations to be acknowledged. 
One limitation is the practice effect associated with the n-back as well as other cognitive 
tasks, which refers to participants improving on the task as a result of repetition of the 
task. Future investigations should examine cognitive tasks that are more robust to the 
practice effect. Another limitation includes the lack of comparison to a placebo, which in 
this investigation was done to reduce the amount of times participants completed the n-
back task. In the future, a between-groups design could be employed with one group 
receiving a placebo condition. Additionally, we detected a treatment by order effect in 
caffeine consumers regarding accuracy, which suggests carry-over between treatments 
may have been present. Thus, employing a longer wash-out period between treatments 
(i.e., > 24 hours) in future investigations may minimize contamination. Finally, the 






educated. Future research should examine the effects of caffeine and acute aerobic 
exercise on WM across various ages, physical activity and education levels.  
Determining the duration of the post-caffeine and post-exercise cognitive benefit, 
as well as investigating the potential effects of different exercise modalities on cognitive 
performance remain areas warranting further investigation. Additionally, examining the 
role of biological variables such as caffeine metabolism via genes such as CYP1A2 could 
further clarify interactions between metabolism and caffeine-driven changes to cognitive 
performance. Finally, exploring the effects of sleep in tandem with caffeine 
administration and acute, aerobic exercise on cognitive functioning is another potential 
avenue of investigation. Through investigations of this nature, the utility of acute, aerobic 
exercise in lieu of caffeine consumption to optimize cognitive performance would be 
further clarified with the end-goal of guiding health-related interventions for both general 
and special populations.  
Conclusion  
Findings from the present study suggest caffeine administration and acute, aerobic 
exercise improve WM accuracy in both non-caffeine and caffeine consumers. 
Furthermore, caffeine administration and acute, aerobic exercise reduce caffeine 
withdrawal symptoms induced by a 12-hour caffeine deprivation period. WM is not 
reduced during caffeine deprivation, hence whether exercise and caffeine can restore WM 
remains unknown. Further research is required to elucidate the mechanisms in which 
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Below is a list of feelings/experiences people have.  Circle the number that best describes how you are 
feeling/what you are experiencing RIGHT NOW. 
 
         Not at all        A little         Moderately       Quite a bit     Extremely  
  
1. Drowsy/sleepy   0  1  2  3  4 
2. Self-confidence   0  1  2  3  4 
3. Yawning    0  1  2  3  4 
4. Alert    0  1  2  3  4 
5. Tired/Fatigued   0  1  2  3  4 
6. Content    0  1  2  3  4 
7. Difficulty Concentrating  0  1  2  3  4 
8. Irritable    0  1  2  3  4 
9. Heavy feelings in arms and legs 0  1  2  3  4 
10. Depressed Mood   0  1  2  3  4 
11. Grouchy    0  1  2  3  4 
12. Urge to do work related activity 0  1  2  3  4 
13. Flu-like feelings   0  1  2  3  4 
14. Headache    0  1  2  3  4 
15. Talkative    0  1  2  3  4 
16. Sluggish    0  1  2  3  4 
17. Upset stomach   0  1  2  3  4 
18. Clearheaded   0  1  2  3  4 
19. Desire to socialize   0  1  2  3  4 
20. Energetic    0  1  2  3  4 
21. Nausea/vomiting   0  1  2  3  4 
22. Muscle pain/stiffness/aches 0  1  2  3  4 
23. Discouraged   0  1  2  3  4 
 
Additional items for consideration:  
Queasy    0  1  2  3  4 
Nauseous    0  1  2  3  4 
Vomiting    0  1  2  3  4  
Headachy    0  1  2  3  4 
*Anxious    0  1  2  3  4 
*Nervous    0  1  2  3  4 
*Jittery     0  1  2  3  4 
*Craving for caffeine   0  1  2  3  4 
*Craving for coffee   0  1  2  3  4 
     





















































Appendix 8. Caffeine Content (Harland, 2000) 
 
Product Serving Size  
(unless otherwise  
stated) 







   
Brewed 8 237(1cup) 135 
Roasted and ground, percolated 8 237 118 
Roasted and ground, filter drip 8 237 179 
Roasted and ground, decaffeinated 8 237 3 
Instant 8 237 76 - 106 
Instant decaffeinated 8 237 5 
  
Product Serving Size  
(unless otherwise  
stated) 















Average blend 8 237 43 
Green 8 237 30 
Instant 8 237 15 
leaf or bag 8 237 50 
Decaffeinated tea 8 237 0 
  
Product Serving Size  
(unless otherwise  
stated) 







   
Cola beverage, regular 12 355(1 can) 36 - 46 






   








1 envelope hot-cocoa mix 8 237 5 
Candy, milk chocolate 1 28g 7 
Candy, sweet chocolate 1 28g 19 
Baking chocolate, unsweetened 1 28g 25 - 58 
Chocolate cake 2.8 80g 36 
Chocolate brownies 1.5 42g 10 
Chocolate mousse 3.2 90g 15 





















Name:   Anisa Morava   
 
Post-secondary  McMaster University  
Education and  Hamilton, Ontario, Canada 
Degrees:   2013-2017 B.Sc. Hons.  
    
   Western University  
   London, Ontario, Canada  
   2017-2019 MA. 
 
 
Honours and   Ontario Graduate Scholarship (OGS) 
Awards:   2017-2018, 2018-2019 
    
   Western Graduate Research Scholarship (WGRS)  
   2017-2018, 2018-2019  
 
 
 
 
 
 
 
